Checkpoint Therapeutics appoints new board member
© Reuters.
WALTHAM, Mass. – Checkpoint Therapeutics , Inc. (NASDAQ:), a clinical-stage immunotherapy and targeted oncology company, today announced the appointment of Dr. Amit Sharma as an independent, non-executive director to its Board of Directors. Dr. Sharma’s current role is Vice President of Clinical Development and Therapeutic Head for Nephrology and Hematology at Alexion (NASDAQ:), AstraZeneca (NASDAQ:) Rare Disease. His appointment is effective immediately.
Dr. Sharma brings a wealth of experience from his previous position as Vice President of Medical Affairs for the Cardiovascular and Renal Division of Bayer (OTC:) Pharmaceuticals. His expertise extends to various senior leadership roles within the biotechnology and larger pharmaceutical industries.
James F. Oliviero, President and CEO of Checkpoint, expressed confidence in Dr. Sharma’s addition to the board, citing his leadership experience in patient care and pharmaceutical product development as valuable assets for the company’s transition into a commercial-stage entity.
Checkpoint Therapeutics is actively developing its lead antibody product candidate, cosibelimab, which is being evaluated as a treatment for patients with certain types of recurrent or metastatic cancers. Additionally, Checkpoint is working on olafertinib, a targeted anti-cancer agent for patients with EGFR mutation-positive non-small cell lung cancer.
Dr. Sharma’s medical degree was obtained from Louisiana State University Medical Center, and he completed his fellowship in nephrology and hypertension at the University of California, San Diego. He holds board certifications in internal medicine, nephrology, and is a certified hypertension specialist.
Checkpoint Therapeutics, founded by Fortress Biotech, Inc. (NASDAQ:), is headquartered in Waltham, MA. The company’s focus is on novel treatments for patients with solid tumor cancers. This article is based on a press release statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
